Pharmacological Intervention in Children with Autism Spectrum Disorder with Standard Supportive Therapies Significantly Improves Core Signs and Symptoms: A Single-Center, Retrospective Case Series
Open Access
- 1 November 2020
- journal article
- research article
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 16, 2779-2794
Abstract
Purpose: Autism spectrum disorder (ASD) is a debilitating neurodevelopmental disorder with high heterogeneity and no clear common cause. Several drugs, in particular risperidone and aripiprazole, are used to treat comorbid challenging behaviors in children with ASD. Treatment with risperidone and aripiprazole is currently recommended by the Food and Drug Administration (FDA) in the USA for children aged 5 and 6 years and older, respectively. Here, we investigated the use of these medications in younger patients aged 4 years and older. Patients and Methods: This retrospective case series included 18 children (mean age, 5.7 years) with ASD treated at the Kids Neuro Clinic and Rehab Center in Dubai. These patients began treatment with risperidone or aripiprazole at the age of 4 years and older, and all patients presented with comorbid challenging behaviors that warranted pharmacological intervention with either risperidone or aripiprazole. Results: All 18 children showed objective improvement in their ASD core signs and symptoms. Significant improvement was observed in 44% of the cases, and complete resolution (minimal-to-no-symptoms) was observed in 56% of the cases as per the Childhood Autism Rating Scale 2-Standard Test (CARS2-ST) and the Clinical Global Impression (CGI) scales. Conclusion: Our findings indicate that the chronic administration of antipsychotic medications with or without ADHD medications is well tolerated and efficacious in the treatment of ASD core and comorbid symptoms in younger children when combined with standard supportive therapies. This is the first report to suggest a treatment approach that may completely resolve the core signs and symptoms of ASD. While the reported outcomes indicate significant improvement to complete resolution of ASD, pharmacological intervention should continue to be considered as part of a multi-component intervention in combination with standard supportive therapies. Furthermore, the findings support the critical need for double-blind, placebo-controlled studies to validate the outcomes.Keywords
This publication has 70 references indexed in Scilit:
- Mandatory electrocardiographic monitoring in young patients treated with psychoactive drugsEuropean Child & Adolescent Psychiatry, 2013
- Hyperconnectivity and Slow Synapses during Early Development of Medial Prefrontal Cortex in a Mouse Model for Mental Retardation and AutismCerebral Cortex, 2012
- Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and AdolescentsJAMA, 2009
- Psychopharmacology and Preschoolers: A Critical Review of Current ConditionsChild and Adolescent Psychiatric Clinics of North America, 2009
- Hyper-connectivity and hyper-plasticity in the medial prefrontal cortex in the valproic acid animal model of autismFrontiers in Neural Circuits, 2008
- Clinical Characteristics of 10 Patients With Continuous Spikes and Waves During Slow Sleep SyndromePediatric Neurology, 2008
- Age-Related Differences in Restricted Repetitive Behaviors in Autism Spectrum DisordersJournal of Autism and Developmental Disorders, 2008
- Cognitive Effects of Risperidone in Children with Autism and Irritable BehaviorJournal of Child and Adolescent Psychopharmacology, 2008
- Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorderEuropean Child & Adolescent Psychiatry, 2007
- Antipsychotic-Induced HyperprolactinaemiaDrugs, 2004